SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 1, 2019--
Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an
underwritten public offering of 5,000,000 shares of its common stock.
All of the shares in the offering will be sold by Tricida. In addition,
Tricida expects to grant the underwriters a 30-day option to purchase up
to an additional 750,000 shares of its common stock in the offering. The
offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and
Company, LLC are acting as joint book-running managers for the offering.
Needham & Company, LLC is acting as co-manager.
A registration statement relating to the offering has been filed with
the Securities and Exchange Commission but has not yet become effective.
The securities may not be sold nor may offers to buy be accepted prior
to the time that the registration statement becomes effective.
The offering is being made only by means of a prospectus. Copies of the
preliminary prospectus relating to the offering may be obtained, when
available, from: Goldman Sachs & Co. LLC, Prospectus Department, 200
West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile:
212-902-9316 or by emailing email@example.com;
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of its drug candidate, TRC101 (veverimer), a
non-absorbed, orally-administered polymer designed to treat metabolic
acidosis in patients with chronic kidney disease (CKD) by binding and
removing acid from the gastrointestinal tract.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005882/en/
Source: Tricida, Inc.
Jackie Cossmon, IRC
Vice President of Investor
Relations and Communications